Masonic Cancer Center

A Comprehensive Cancer Center designated by the National Cancer Institute

Find a Clinical Trial

Quick Search (by title or disease)
  

Go to Advanced Search for more options.

Clinical Trials Help
Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

  Sip Protocol

Masonic Cancer Research Center
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Back to Search Instructions

Protocol No. 2012CG103 Principal Investigator Moertel, Christopher
Phase Phase II
Age Group Children Scope National
Secondary Protocol No. ACNS0821
Title COG ACNS0821 - Temozolomide with Irinotecan versus temozolomine, Irinotecan plus Bevacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Applicable Disease Sites Brain and Nervous System
Drugs Involved Bevacizumab
IRINOTECAN (CPT-11, CAMPTOSAR)
TEMOZOLAMIDE (TEMODAL)
Status Open
Participating Institutions Masonic Cancer Center
Treatment Type Treatment
Contact Tambra Dahlheimer Phone:612-626-2629
Email:tdahlheimer@umphysicians.umn.edu
  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on